Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT.

Ostronoff F, Perales MA, Stubblefield MD, Hsu KC.

Bone Marrow Transplant. 2008 Jul;42(1):71-2. doi: 10.1038/bmt.2008.81. Epub 2008 Apr 7. No abstract available.

2.

Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT.

Lee HJ, Gulbis A, De Padua Silva L, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SO.

Bone Marrow Transplant. 2008 Jul;42(1):67-9. doi: 10.1038/bmt.2008.79. Epub 2008 Mar 17. Review. No abstract available.

PMID:
18347568
3.

Guillain-Barré syndrome after transplantation.

Zhang L, Arrington S, Keung YK.

Leuk Lymphoma. 2008 Feb;49(2):291-7. doi: 10.1080/10428190701760003.

PMID:
18231916
4.

Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation.

Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA.

Bone Marrow Transplant. 2002 Mar;29(6):515-7.

5.

Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy.

Crocchiolo R, Ciccolini J, El-Cheikh J, Fürst S, Castagna L, Granata A, Oudin C, Harbi S, Devillier R, Legall S, Ternant D, Paintaud G, Lacarelle B, Blaise D.

Leuk Lymphoma. 2012 Oct;53(10):2063-5. doi: 10.3109/10428194.2012.670232. Epub 2012 Apr 19. No abstract available.

PMID:
22372847
6.

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91. doi: 10.1016/j.bbmt.2009.10.008. Epub 2009 Oct 14.

7.

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.

Biol Blood Marrow Transplant. 2011 Jun;17(6):901-7. doi: 10.1016/j.bbmt.2010.10.003. Epub 2010 Oct 13.

8.

Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.

Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R.

Transpl Infect Dis. 2013 Jun;15(3):259-67. doi: 10.1111/tid.12061. Epub 2013 Feb 13.

PMID:
23405972
9.

Successful control of steroid-intolerant Evans' syndrome associated with allogeneic peripheral blood hematopoietic stem cell transplant by rituximab.

Ryeon Lee S, Lee SY, Nam MH, Park Y, Jong Park S, Jung Sung H, Won Choi C, Soo Kim B.

Leuk Lymphoma. 2011 Mar;52(3):528-30. doi: 10.3109/10428194.2010.538940. Epub 2011 Jan 28. No abstract available.

PMID:
21275632
10.

Rituximab treatment may disturb the normal pattern of lymphopoiesis after cord blood SCT.

Barba P, Garcia-Cadenas I, Nomdedéu J, Martino R, Gallur L, Valcárcel D.

Bone Marrow Transplant. 2012 Mar;47(3):458-60. doi: 10.1038/bmt.2011.98. Epub 2011 May 9. No abstract available.

PMID:
21552304
11.

Guillain-Barré syndrome after human herpesvirus-6 reactivation in unrelated hematopoietic stem cell transplantation.

Piras E, Caocci G, Pisano V, Orrù F, Murgia F, Sanna M, Vacca A, La Nasa G.

Leuk Lymphoma. 2013 Jun;54(6):1332-3. doi: 10.3109/10428194.2012.740560. Epub 2013 Mar 4. No abstract available.

PMID:
23088724
12.

Long-term results of rituximab treatment for membranous nephropathy after allogeneic hematopoietic SCT: a case report.

Mattei D, Sorasio R, Guarnieri A, Marazzi F, Formica M, Fortunato M, Mordini N, Rapezzi D, Gallamini A.

Bone Marrow Transplant. 2010 Jun;45(6):1111-2. doi: 10.1038/bmt.2009.276. Epub 2009 Sep 28. No abstract available.

PMID:
19784075
13.

Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.

Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X, Zhang F, Liu C, Sun J, Huang X.

Am J Hematol. 2013 Jul;88(7):550-5. doi: 10.1002/ajh.23452. Epub 2013 May 30.

14.

Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.

Vischini G, Cudillo L, Ferrannini M, Di Daniele N, Cerretti R, Arcese W.

J Nephrol. 2009 Jan-Feb;22(1):160-3.

PMID:
19229832
15.

Treatment advances in posttransplant lymphoproliferative disease.

DiNardo CD, Tsai DE.

Curr Opin Hematol. 2010 Jul;17(4):368-74. doi: 10.1097/MOH.0b013e328339018c. Review.

PMID:
20473161
16.

Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.

Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.

Clin Transplant. 2013 Jul-Aug;27(4):E491-7. doi: 10.1111/ctr.12172. Epub 2013 Jun 19.

PMID:
23781897
17.

Guillain-Barré syndrome after autologous peripheral blood stem cell transplantation for CML.

Janssen JJ, Tissingh G, Ossenkoppele GJ.

Eur J Haematol. 1999 Nov;63(5):358-9. No abstract available.

PMID:
10580569
18.

Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab.

Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AK, Kwong YL.

Br J Haematol. 2007 Jun;137(5):475-8. Epub 2007 Apr 13.

PMID:
17433026
19.
20.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Styczynski J, Einsele H, Gil L, Ljungman P.

Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Review.

PMID:
19558376

Supplemental Content

Support Center